Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29477665

Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Apr
First author
Maio M

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Apr;19(4):436-437. doi: 10.1016/S1470-2045(18)30150-5.
    note
    Source null
    related pmid
    29477664
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2018 May;15(5):265. doi: 10.1038/nrclinonc.2018.39.
    note
    Source null
    related pmid
    29532799
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2018 Apr;19(4):e184. doi: 10.1016/S1470-2045(18)30209-2.
    note
    Source null
    related pmid
    29611525
    relationship
    Erratum in

Authors and identifiers

  1. name
    Maio M
    type
    Author
  2. name
    Lewis K
    type
    Author
  3. name
    Demidov L
    type
    Author
  4. name
    Mandalà M
    type
    Author
  5. name
    Bondarenko I
    type
    Author
  6. name
    Ascierto PA
    type
    Author
  7. name
    Herbert C
    type
    Author
  8. name
    Mackiewicz A
    type
    Author
  9. name
    Rutkowski P
    type
    Author
  10. name
    Guminski A
    type
    Author
  11. name
    Goodman GR
    type
    Author
  12. name
    Simmons B
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Maio M
    type
    Author
  2. name
    Lewis K
    type
    Author
  3. name
    Demidov L
    type
    Author
  4. name
    Mandalà M
    type
    Author
  5. name
    Bondarenko I
    type
    Author
  6. name
    Ascierto PA
    type
    Author
  7. name
    Herbert C
    type
    Author
  8. name
    Mackiewicz A
    type
    Author
  9. name
    Rutkowski P
    type
    Author
  10. name
    Guminski A
    type
    Author
  11. name
    Goodman GR
    type
    Author
  12. name
    Simmons B
    type
    Author
bibliography ids
  1. nci-bib-fbd37aeeb6a3225d92abd20b
book metadata
content sha256
b93368cc242493ff9b4c439d1d547b5c857d2be2941d2ef2c0128e54e5ecea4c
document type
citation
dois
  1. 10.1016/S1470-2045(18)30106-2
electronic publication date
display
2018 Feb 21
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29477665
immutable id
pubmed:29477665@b93368cc242493ff9b4c439d1d547b5c857d2be2941d2ef2c0128e54e5ecea4c
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
4
name
The Lancet. Oncology
nlm unique id
100957246
pages
510-520
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Apr;19(4):436-437. doi: 10.1016/S1470-2045(18)30150-5.
    note
    Source null
    related pmid
    29477664
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2018 May;15(5):265. doi: 10.1038/nrclinonc.2018.39.
    note
    Source null
    related pmid
    29532799
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2018 Apr;19(4):e184. doi: 10.1016/S1470-2045(18)30209-2.
    note
    Source null
    related pmid
    29611525
    relationship
    Erratum in
outcomes validated
false
pmid
29477665
provenance
batch id
ec9444d0f4cade22eb9f
provider
NCBI PubMed ESummary
record sha256
e993c14218578a10d299b3fc7e7dbed7fa0d632a70957705c556c4cf9bdd6a18
response sha256
6eef0d8cc09b77e73af656f6390cc734befb84fbc4c229b886e81e5d95bece31
retrieved at
2026-09-09T23:47:30.975610+00:00
publication date
display
2018 Apr
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29477665/
title
Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Preserved source evidence · Not medical advice